ImmunityBio, Inc.: Form 10-K for the period ended Dec 31, 2015
Filed with the SEC on Mar 30, 2016 and accepted by EDGAR at Mar 30, 2016, 13:00 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2015-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2015-10-01 to 2015-12-31 | $15.0k | us-gaap:Revenues |
| Revenue | 12 months2015-01-01 to 2015-12-31 | $236.0k | us-gaap:Revenues |
| Research and development | 12 months2015-01-01 to 2015-12-31 | $11.4m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2015-10-01 to 2015-12-31 | $25.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 12 months2015-01-01 to 2015-12-31 | $227.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Income tax | 12 months2015-01-01 to 2015-12-31 | −$301.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2015-10-01 to 2015-12-31 | −$26.8m | us-gaap:NetIncomeLoss |
| Net income | 12 months2015-01-01 to 2015-12-31 | −$236.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2015-10-01 to 2015-12-31 | −$0.33 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 12 months2015-01-01 to 2015-12-31 | −$3.31 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months2015-01-01 to 2015-12-31 | −$25.3m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 12 months2015-01-01 to 2015-12-31 | $2.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2015-01-01 to 2015-12-31 | $4.8m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2015-12-31 | $175.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current liabilities | At period end2015-12-31 | $6.1m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2015-12-31 | $356.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-16-015596. Last ingested by Listed: Nov 9, 2026, 17:45 ET. Listed shows no prices and gives no investment advice.